Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2015
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer.BMC cancer · 2021Pooled it
- The significant prognostic value of circulating tumor cells in triple-negative breast cancer: a meta-analysis.Oncotarget · 2016Pooled it
- Circulating tumour cells at baseline and late phase of treatment provide prognostic value in breast cancer.Scientific reports · 2021Trial
- Liquid biopsy in TNBC: significance in diagnostics, prediction, and treatment monitoring.Frontiers in oncology · 2025Review
- Label-Free Microfluidic Apheresis of Circulating Tumor Cell Clusters.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Circulating tumor cells clusters and their role in Breast cancer metastasis; a review of literature.Discover oncology · 2024Review
- Review
- The metastatic niche formation: focus on extracellular vesicle-mediated dialogue between lung cancer cells and the microenvironment.Frontiers in oncology · 2023Review
- Modelling metastasis in zebrafish unveils regulatory interactions of cancer-associated fibroblasts with circulating tumour cells.Frontiers in cell and developmental biology · 2023Article
- Clinical Relevancy of Circulating Tumor Cells in Breast Cancer: Epithelial or Mesenchymal Characteristics, Single Cells or Clusters?International journal of molecular sciences · 2022Review
- The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HRAnnals of translational medicine · 2022Article
- Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer.Breast cancer research and treatment · 2022Article
- The Role of Circulating Tumor Cells in the Prognosis of Metastatic Triple-Negative Breast Cancers: A Systematic Review of the Literature.Biomedicines · 2022Review
- Mechanisms of breast cancer metastasis.Clinical & experimental metastasis · 2022Review
- Better together: circulating tumor cell clustering in metastatic cancer.Trends in cancer · 2021Review
- Dissecting Breast Cancer Circulating Tumor Cells Competence via Modelling Metastasis in Zebrafish.International journal of molecular sciences · 2021Article
- Collective metastasis: coordinating the multicellular voyage.Clinical & experimental metastasis · 2021Review
- Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer.Cancers · 2021Article
- Article
- Characterization of circulating tumor cells in early breast cancer patients receiving neoadjuvant chemotherapy.Therapeutic advances in medical oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 11 institutions in 1 country.
Funding
Abstract
purposeCirculating tumor cells (CTC) are prognostic in metastatic breast cancer (MBC). We tested whether EpCAM-based capture system (CellSearch) is effective in patients with triple-negative (TN) MBC, and whether CTC apoptosis and clustering enhances the prognostic role of CTC. EXPERIMENTAL
designCTC enumeration and apoptosis were determined using the CXC CellSearch kit at baseline and days 15 and 29 in blood drawn from TN MBC patients who participated in a prospective randomized phase II trial of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) with or without tigatuzumab. Association between levels of CTC and patient outcomes was assessed using logistic regression, Kaplan-Meier curves, and Cox proportional hazards modeling.
resultsNineteen of 52 (36.5%), 14 of 52 (26.9%), and 13 of 49 (26.5%) patients who were evaluable had elevated CTC (≥5 CTC/7.5 mL whole blood) at baseline and at days 15 and 29, respectively. Patients with elevated versus not elevated CTC at each time point had worse progression-free survival (PFS; P = 0.005, 0.0003, 0.0002, respectively). The odds of clinical benefit response for those who had elevated versus low CTC at baseline and days 15 and 29 were 0.25 (95% CI: 0.08-0.84; P = 0.024), 0.19 (95% CI: 0.05-0.17; P = 0.014), and 0.06 (95% CI: 0.01-0.33; P = 0.001), respectively. There was no apparent prognostic effect comparing CTC apoptosis versus non-apoptosis. Presence of CTC cluster at day 15 and day 29 was associated with shorter PFS.
conclusionsCTC were detected using CellSearch assay in approximately one-third of TN MBC patients. Elevated CTC at baseline and days 15 and 29 were prognostic, and reductions in CTC levels reflected response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.